Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameMediwelcome
Stock Code02159
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities主要提供(i)醫學會議服務、(ii)患者教育及自測服務及(iii)營銷戰略和諮詢服務,目標為解決心腦血管疾病醫療生態系統各主要利益相關者的未滿足需求,並彌合該等利益相關者之間的距離。亦於2019年年底開始提供CRO服務及互聯網醫院服務。
Listing Date2021-01-19
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京市朝陽區東四環北路2號上東公園里10-12層
Business Address (Hong Kong)香港禧利街27號富輝商業中心22樓2204室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.mediwelcome.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 3.00 / shares
Offer Price RangeFinal offer price only, no range
Lot Size800 shares
Entry ThresholdHK$ 2,400
Par ValueTo be extracted
Offer Period2020-12-31 to 2021-01-08
Global Offering Shares50,000,000 shares
HK Public Offer Shares (Initial)5,000,000 shares (10.0%)
Public Offer Lots (Initial)6,250lots (Pool A3,125lots,Pool B3,125lots)
International Placing Shares (Initial)45,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO200,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 150,000,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 800 HK$ 2,400
2 lots 1,600 HK$ 4,800
3 lots 2,400 HK$ 7,200
4 lots 3,200 HK$ 9,600
5 lots 4,000 HK$ 12,000
6 lots 4,800 HK$ 14,400
7 lots 5,600 HK$ 16,800
8 lots 6,400 HK$ 19,200
9 lots 7,200 HK$ 21,600
10 lots 8,000 HK$ 24,000
15 lots 12,000 HK$ 36,000
20 lots 16,000 HK$ 48,000
25 lots 20,000 HK$ 60,000
30 lots 24,000 HK$ 72,000
35 lots 28,000 HK$ 84,000
40 lots 32,000 HK$ 96,000
45 lots 36,000 HK$ 108,000
50 lots 40,000 HK$ 120,000
75 lots 60,000 HK$ 180,000
100 lots 80,000 HK$ 240,000
125 lots 100,000 HK$ 300,000
150 lots 120,000 HK$ 360,000
175 lots 140,000 HK$ 420,000
200 lots 160,000 HK$ 480,000
225 lots 180,000 HK$ 540,000
250 lots 200,000 HK$ 600,000
375 lots 300,000 HK$ 900,000
500 lots 400,000 HK$ 1,200,000
625 lots 500,000 HK$ 1,500,000
750 lots 600,000 HK$ 1,800,000
875 lots 700,000 HK$ 2,100,000
1,000 lots 800,000 HK$ 2,400,000
1,125 lots 900,000 HK$ 2,700,000
1,250 lots 1,000,000 HK$ 3,000,000
1,500 lots 1,200,000 HK$ 3,600,000
1,750 lots 1,400,000 HK$ 4,200,000
2,000 lots 1,600,000 HK$ 4,800,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
2,250 lots 1,800,000 HK$ 5,400,000
2,500 lots 2,000,000 HK$ 6,000,000
2,750 lots 2,200,000 HK$ 6,600,000
3,125 lots 2,500,000 HK$ 7,500,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 534.5M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +1717%

Valuation & Financials

Market Cap (at Offer Price)HK$ 600,000,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣22.1百萬元
Period-End Cash Balance人民幣73.6百萬元
Listing Expenses~HK$ 64,200,000
Listing Expenses / Funds Raised~42.8%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201720182019
Revenue 258,880298,968427,159
Cost of sales -187,506-214,372-332,291
Gross profit 71,37484,59694,868
Other income and gains, net 5732,2903,339
Selling and distribution expenses -4,180-4,636-6,377
Administrative expenses -23,643-26,384-34,196
Net finance costs -268-301-309
Profit before tax 38,11849,15225,972
Income tax expense -7,902-9,475-3,915
Profit for the year 30,21639,67722,057
Profit attributable to owners 29,65738,04120,852
Balance Sheet
Item 2017201820192020-06
Cash and cash equivalents 90,21999,20573,642
Trade and bills receivables 27,53030,66571,719
Total current assets 129,348142,284179,896
Total assets 140,256203,173229,481
Total current liabilities 40,95573,62183,491
Total equity 98,735126,586144,805
Equity attributable to owners 93,939118,907135,921
Interest-bearing borrowings 2,9608,0724,16437,155
Cash Flow Statement
Item 2017201820192020-06
Net cash from operating activities -1,64158,8394,515
Net cash from investing activities 2,460-30,383-24,523
Net cash from financing activities 31,179-19,470-5,555
Net increase in cash 31,9988,986-25,563
Depreciation of PP&E 2,8792,6522,6661,406
Depreciation of right-of-use assets 5,2625,4345,3523,000
Amortisation of intangible assets 812212,7113,336
Purchase of PP&E -3,138-3,131-2,138-3,450
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 3.79
First Day OpenHK$ 4.0
First Day Change26.33%
First Day Volume100586000.0
First Day Turnover402943000.0
Use of Proceeds
1、估計總所得款項凈額約58%或51.8百萬港元用于拓展我們的客戶群、疾病覆蓋范圍及患者群; 2、估計總所得款項凈額約25%或22.3百萬港元用于發展我們的互聯網醫院服務; 3、估計總所得款項凈額約12%或10.7百萬港元用于運營資金及一般公司用途; 4、估計總所得款項凈額約5%或4.5百萬港元發展CRO服務,包括招募經驗豐富的員工團隊。

Underwriting Syndicate

Sole Sponsor (1)
CEB International Capital Corporation Limited CE BGH296
Joint Bookrunners (5)
CEB International Capital Corporation Limited CE BGH296 ARISTO SECURITIES LIMITED CE BDH167 交银国际证券有限公司 CE APJ121 民银证券有限公司 CE APU820 SPDB International Capital Limited CE BFZ375
Joint Lead Managers (7)
CEB International Capital Corporation Limited CE BGH296 ARISTO SECURITIES LIMITED CE BDH167 交银国际证券有限公司 CE APJ121 民银证券有限公司 CE APU820 Ruibang Securities Limited CE BIJ312 SPDB International Capital Limited CE BFZ375 BETA INTERNATIONAL SECURITIES LIMITED CE ABN652

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman施煒—
Company Secretary趙魯陽、梁慧玲—
No director data available.

Major Shareholders

Major Shareholders & Holdings施煒先生、楊為民先生、張藝濤女士及王亮先生為一致行動人士,透過各自全資公司(霽澤投資、舜嘉投資、禾匯萬怡投資、泰之豐投資)共同持有103,519,000股,緊隨全球發售完成後約佔51.76%。RSU Holdings持有20,000,000股,約10.0%。
About this page

This page shows Mediwelcome (02159) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect